biomedicina slovenica


"Dopamine" : 325

  1. Sočan Vesna; Kržan Mojca
    The uptake of [3H]dopamine into cultured neonatal rat astrocytes involves multiple transporters
    2022
  2. Zobec Lea; Zajc Irena; Sočan Vesna; Kržan Mojca; Žiberna Lovro
    Effect of selected drug compounds on dopamine cytotoxicity on human endothelial cells and rat astrocytes
    2022
  3. Šalamon Arčan Iris; Kouter Katarina; Videtič Paska Alja
    Depressive disorder and antidepressants from an epigenetic point of view
    2022
  4. Umek Nejc
    The effects of biologically important divalent and trivalent metal cations on the cyclization step of dopamine autooxidation reaction
    2022
  5. Redenšek Trampuž Sara; Kristanc Tilen; Blagus Tanja; Trošt Maja; Dolžan Vita
    Genetic variability of the vitamin D receptor affects susceptibility to Parkinson's disease and dopaminergic treatment adverse events
    2022
  6. Redenšek Sara; Kristanc Tilen; Blagus Tanja; Trošt Maja; Dolžan Vita
    Genetska variabilnost receptorja za vitamin D vpliva na dovzetnost za parkinsonovo bolezen in pojav neželenih učinkov dopaminergičnega zdravljenja
    2022
  7. Zupan Amadea
    Depresija in prehrana
    [Depression and nutrition]
    2022
  8. Kolmančič Kaja; Živin Marko; Zorović Maja
    Modulation by estradiol of L-dopa-induced dyskinesia in a rat model of post-menopausal hemiparkinsonism
    2022
  9. Žabkar Ines; Zorović Maja
    Učinki estrogena na profil izražanja genov v dopaminsko denervirani možganski hemisferi
    2020
  10. Redenšek Sara; Trošt Maja; Dolžan Vita
    Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson's disease
    2018
  11. Redenšek Sara; Trošt Maja; Dolžan Vita
    Genetic variability in oxidative stress pathways influences the occurrence of adverse events of dopaminergic treatment in Parkinson's disease
    2018
  12. Redenšek Sara; Blagus Tanja; Trošt Maja; Dolžan Vita
    Serotonin-related functional genetic variants affect the occurrence of psychiatric and motor adverse events of dopaminergic treatment in Parkinson’s disease
    2022
  13. Tsermpini Evangelia Erini; Redenšek Sara; Dolžan Vita
    Genetic factors associated with tardive dyskinesia
    2022
  14. Assimakopoulos Konstantinos; Karaivazoglou Katerina; Skokou Maria; Kalogeropoulou Marina; Kolios Panagiotis; Gourzis Philippos; Patrinos George P.; Tsermpini Evangelia Erini
    Genetic variations associated with sleep disorders in patients with schizophrenia
    2018
  15. Korecka Joanna A.; Moloney Elizabeth B.; Eggers Ruben; Hobo Barbara; Scheffer Sanny; Ras-Verloop Nienke; Pasterkamp R. Jeroen; Swaab Dick Frans; Smit August B.; Van Kestere Ronald E.
    Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson's disease
    2017
  16. Fang Qiuyuan; Xicoy Helena; Shen Junqing; Luchetti Sabina; Dai Di; Zhou Pei; Qi Xin-Rui; Martens Gerard J.M.; Huitinga Inge; Swaab Dick Frans
    Histamine-4 receptor antagonist ameliorates Parkinson-like pathology in the striatum
    2021
  17. Schulte Eva C.; Altmaier Elisabeth; Berger Hannah S.; Trinh Do Kieu; Kastenmüller Gabi; Wahl Simone; Adamski Jerzy; Peters Annette; Krumsiek Jan; Suhre Karsten
    Alterations in lipid and inositol metabolisms in two dopaminergic disorders
    2016
  18. Zorović Maja; Kolmančič Kaja; Živin Marko
    Effects of L-dopa on expression of prolactin and synaptotagmin IV in 17[beta]-estradiol-induced prolactinomas of ovariectomized hemiparkinsonian rats
    2021
  19. Ramos-Gonzalez Paula; Mato Susana; Chara Juan Carlos; Verkhratsky Alexei; Matute Carlos; Cavaliere Fabio
    Astrocytic atrophy as a pathological feature of Parkinson's disease with LRRK2 mutation
    2021
  20. Hartleben Goetz; Schorpp Kenji; Kwon Yun; Betz Barbara; Tsokanos Foivos-Filippos; Dantes Zahra; Schäfer Arlett; Rothenaigner Ina; Manuel José; Adamski Jerzy
    Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism
    2021
  21. Ferlan Aleksandra; Sket Dušan
    Dopaminergična aktivnost [alfa]-ergozina in 2-Br-[alfa]-ergozina
    1979
  22. Levstek Tina; Redenšek Sara; Trošt Maja; Dolžan Vita; Trebušak Podkrajšek Katarina
    Assessment of the telomere length and its effect on the symptomatology of Parkinson's disease
    2021
  23. Pirc Marolt Tinkara; Kramar Barbara; Bulc Rozman Klara; Šuput Dušan; Milisav Irina
    Aripiprazole reduces liver cell division
    2020
  24. Blagotinšek Cokan Kaja; Mavri Maša; Rutland Catrin; Glisic Sanja; Sencanski Milan; Vrecl Milka; Kubale Valentina
    Critical impact of different conserved endoplasmic retention mofits and dopamine receptor interacting proteins (DRIPs) on intracellular localization and trafficking of the D2 dopamine receptor (D2-R) isoforms
    2020
  25. Redenšek Sara; Dolžan Vita
    The role of pharmacogenomics in personalization of the Parkinson's disease treatment
    2020
  26. Redenšek Sara; Jenko Bizjan Barbara; Trošt Maja; Dolžan Vita
    Clinical and clinical-pharmacogenetic models for prediction of the most common psychiatric complications due to dopamingeric treatment in Parkinson's disease
    2020
  27. Huber Eva Maria; Beyer Leonie; Prix Catharina; Schönecker Sonja; Palleis Carla; Rauchmann Boris-Stephan; Morbelli Silvia; Chincarini Andrea; Bruffaerts Rose; Vandenberghe Rik; Trošt Maja; Gregorič Kramberger Milica; Grmek Marko
    Metabolic correlates of dopaminergic loss in dementia with lewy bodies
    2020
  28. Rus Tomaž; Jamšek Jan; Berlot Rok; Šurlan Popović Katarina; Grmek Marko; Trošt Maja
    Nuklearnomedicinske preiskave pri diagnosticiranju demence in parkinsonizmov
    [Nuclear medicine investigations in dementia and parkinsonism]
    2020
  29. Lavrin Teja; Konte Tilen; Kostanjšek Rok; Sitar Simona; Sepčić Kristina; Prpar Mihevc Sonja; Žagar Ema; Župunski Vera; Lenassi Metka; Rogelj Boris; Gunde-Cimerman Nina
    The neurotropic black yeast Exophiala dermatitidis induces neurocytotoxicity in neuroblastoma cells and progressive cell death
    2020
  30. Nettleton Jodi E.; Klančič Teja; Schick Alana; Choo Ashley C.; Shearer Janet; Borgland Stephanie L.; Chleil Faye; Mayengbam Shyamchand; Reimer Raylene A.
    Low-dose Stevia (Rebaudioside A) consumption perturbs gut microbiota and the mesolimbic dopamine reward system
    2019
  31. Schwarzlin Romina; Salam Sejjad; Pušenjak Nika
    Balancing the apoptotic switch - from cancer to Parkinsonʼs disease
    2017
  32. Redenšek Sara; Trošt Maja; Dolžan Vita
    Genetic polymorphisms in dopaminergic pathway influence the occurrence of adverse events of dopaminergic treatment in Parkinson's disease
    2019
  33. Redenšek Sara; Jenko Barbara; Trošt Maja; Dolžan Vita
    Clinical-pharmacogenetic predictive models for time to occurrence of levodopa related motor complications in Parkinson's disease
    2019
  34. Redenšek Sara; Flisar Dušan; Kojović Maja; Gregorič Kramberger Milica; Georgiev Dejan; Pirtošek Zvezdan; Trošt Maja; Dolžan Vita
    Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease
    2019
  35. Sikirić Predrag; Seiwerth Sven; Ručman Rudolf; Turkovic Branko; Stancic-Rokotov Dinko; Brcic Luka; Sever Marko; Klicek Robert; Radic Bozo; Kolenc Danijela
    Stable gastric pentadecapeptide BPC 157
    2011
  36. Sikirić Predrag; Seiwerth Sven; Ručman Rudolf; Kolenc Danijela; Batelja Vuletic Lovorka; Drmić Domagoj; Grgic Tihomir; Strbe Sanja; Zukanovic Goran; Crvenkovic Dalibor
    Brain-gut axis and pentadecapeptide BPC 157
    2016
  37. Iskra Vugdelija Lina; Kržan Mojca; Žiberna Lovro
    Osnovne značilnosti privzema dopamina v astrocite novorojene podgane
    2018
  38. Redenšek Sara; Flisar Dušan; Kojović Maja; Gregorič Kramberger Milica; Georgiev Dejan; Pirtošek Zvezdan; Trošt Maja; Dolžan Vita
    Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease
    2019
  39. Pišlar Anja; Tratnjek Larisa; Glavan Gordana; Živin Marko; Kos Janko
    Upregulation of cysteine protease cathepsin X in the 6-hydroxydopamine model of Parkinson's disease
    2018
  40. Redenšek Sara; Trošt Maja; Dolžan Vita
    The effect of inflammation-related genetic polymorphisms on the occurrence of non-motor adverse events of dopaminergic treatment in Parkinson's disease
    2018
  41. Redenšek Sara; Trošt Maja; Dolžan Vita
    Vpliv genetskih dejavnikov na izid dopaminergičnega zdravljenja Parkinsonove bolezni
    2017
  42. Rektor Ivan; Bohnen Nicolaas I.; Korczyn Amos D.; Gryb Viktoria; Kumar Hrishikesh; Gregorič Kramberger Milica; de Leeuw Frank-Erik; Pirtošek Zvezdan; Rektorova Irena; Schlesinger Ilana
    An updated diagnostic approach to subtype definition of vascular parkinsonism
    2018
  43. Šet Vida; Šinkovec Jaka; Trošt Maja
    Dopaminski disregulacijski sindrom pri bolnikih s Parkinsonovo bolezijo
    [Dopamine dysregulation syndrome in Parkinson's disease patients]
    2017
  44. Turčin Arijana; Dolžan Vita; Porcelli Stefano; Serretti Alessandro; Kores-Plesničar Blanka
    Adenosine hypothesis of antipsychotic drugs revisited
    2016
  45. Terzič Tea; Kastelic Matej; Dolžan Vita; Kores-Plesničar Blanka
    Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia
    2016
  46. Bogićević Sanja; Živin Marko
    Efficacy of potential atypical antipsychotic lek-8829 on behavioral effects in rat model of catalepsy and inhibition of amphetamine induced psychomotor stimulation
    [[Učinkovitost potencialnega atipičnega antipsihotika lek-8829 na vedenjske učinke na podganjih modelih katalepsije ter z amfetaminom povzročene psihomotorične stimulacije]]
    2015
  47. Tratnjek Larisa; Glavan Gordana; Višnjar Tanja; Živin Marko
    Up-regulation and axonal transport of synaptotagmin-IV in the direct pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulation
    2016
  48. Dolžan Vita; Kores-Plesničar Blanka; Serretti Alessandro; Mandelli Laura; De Ronchi Diana; Olgiati Paolo; Zalar Bojan; Koprivšek Jure; Breskvar Katja
    Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment
    2006
  49. Huang Yu-Ting; Georgiev Dejan; Foltynie Tom; Limousin Patricia; Speekenbrink Maarten; Jahanshahi Marjan
    Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions
    2015
  50. Batagelj Nevenka; Jensterle Sever Mojca; Dolžan Vita
    Genetska variabilnost dopaminergičnega sistema in izločanje inzulina ter metabolični odgovor na zdravljenje pri bolnicah s sindromom policističnih ovarijev
    2015
  51. Štemberger Nastja; Tratnjek Larisa; Živin Marko
    Dopaminergic modulation of synaptotagmin IV and substance P expression and characterization of striatal alterations during culture of organotypic whole brain slices from young rats
    2015
  52. Kapraljević Ana; Tratnjek Larisa; Živin Marko
    The effect of acute ibogaine treatment on the survival of dopaminergic neurons in organotypic nigrostriatal Co - cultures
    2015
  53. Tratnjek Larisa; Glavan Gordana; Živin Marko
    Dopaminergic modulation of synaptotagmin IV expression in animal model of Parkinson disease
    2015
  54. Bajrović Fajko; Jugović Domagoj; Milutinović Živin Aleksandra; Glavan Gordana; Tratnjek Larisa; Glišović Špela; Saghafi Mehdi M.; Živin Marko
    Synaptotagmin 4mRNA expression as an inducible indicator of dopaminergic hyperexcitation and of glutamatergic excitotoxicity
    2015
  55. Rodríguez José J.; Noristani Harun N.; Verkhratsky Alexei
    The serotonergic system in ageing and Alzheimer's disease
    2012
  56. L'Episcopo F.; Tirolo C.; Testa N.; Caniglia S.; Morale M. C.; Cossetti M. C.; D'Adamo Patrizia; Zardini E.; Andreoni L.; Ihekwaba A. E. C.
    Reactive astrocytes and Wnt/[beta]-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    2011
  57. Wilson Gabrielle R.; Sim Joe C. H.; McLean Catriona; Giannandrea Maila; Galea Charles A.; Riseley Jessica R.; Stephenson Sarah E. M.; Fitzpatrick Elizabeth; Haas Stefan A.; D'Adamo Patrizia
    Mutations in RAB39B cause X-linked intellectual disability and early-onset parkinson disease with [alpha]-synuclein pathology
    2014
  58. Locatelli Igor; Mrhar Aleš
    Odmerjanje zdravil za zdravljenje Alzheimerjeve in Parkinsonove bolezni
    [Dosage regimens of drugs used in the treatment of Alzheimer's and Parkinson's disease]
    2008
  59. Devjak Rok; Fon Tacer Klementina; Juvan Peter; Virant-Klun Irma; Rozman Damjana; Vrtačnik-Bokal Eda
    Cumulus cells gene expression profiling in terms of oocyte maturity in controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist
    2012
  60. Rojc Žan; Komel Radovan; Videtič Paska Alja
    Preiskava polimorfizmov v genu DRD2 pri žrtvah samomora
    2014
  61. Kubale Valentina; Blagotinšek Kaja; Pogačnik Azra; Vrecl Milka
    Vloga tretje znotrajcelične zanke pri regulaciji dolge oblike dopaminskega receptotja tipa 2 (D2L-R)
    2011
  62. Rubio-Agusti Ignacio; Kojović Maja; Edwards Mark J.; Murphy Elaine; Chandrashekar Hoskote S.; Lachmann Robin H.; Bhatia Kailash P.
    Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review
    2012
  63. Bologna Matteo; Kojović Maja
    Interfacing basal ganglia models and Parkinson's disease phenomenology
    2012
  64. Grgurevič Neža; Strle Drago; Trifković Mario; Majdič Gregor
    Development of novel electrochemical biosensors for detection of neurotransmitters
    2013
  65. Tratnjek Larisa; Glavan Gordana; Živin Marko
    Dopaminergic modulation of striatalexpression of Synaptotagmin IV
    2013
  66. Moretti Rita; Torre Paola; Antonello Rodolfo M.; Vidus Rosin Marta; Esposito Francesca; Rubelli Furman Matej; Bellini Giuseppe
    Apathy
    2012
  67. Groznik Vida; Guid Matej; Sadikov Aleksander; Možina Martin; Georgiev Dejan; Kragelj Veronika; Ribarič Samo; Pirtošek Zvezdan; Bratko Ivan
    Elicitation of neurological knowledge with argument-based machine learning
    2013
  68. Siedlinski Mateuzs; Cho Michael H; Bakke Per; Košnik Mitja
    Genome-wide association study of smoking behaviours in patients with COPD
    2011
  69. Blagotinšek Kaja; Kubale Valentina; Pogačnik Azra; Vrecl Milka
    Identification of conserved motif in the third intracellular loop in dopamine receptor type 2 (D2L-R) related to intracellular retention of D2L-R
    2012
  70. Ribarič Samo
    The pharmacological properties and therapeutic use of apomorphine
    2012
  71. Jukić Tomislav; Rojc Bojan; Boben-Bardutzky Darja; Hafner Mateja; Ihan Alojz
    The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms
    2011
  72. Šubic Ana; Steblovnik Tjaša
    Vpliv kontinuirane dopaminergične stimulacije z ropinirolom na nemotorične simptome in kakovost življenja bolnikov s Parkinsonovo boleznijo
    2011
  73. Trošt M; Starovasnik-Žagavec B; Tomše P; Čuš A; Slodnjak I; Vodušek D; Pirtošek Z
    Cognitive and motor function correlation with brain activity in early Parkinson's disease and the effect of dopaminergic treatment
    2011
  74. Šubic Ana; Steblovnik Tjaša
    Vpliv kontinuirane dopaminergične stimulacije z ropinirolom na nemotorične simptome in kakovost življenja bolnikov s Parkinsonovo boleznijo
    2010
  75. Tomše Petra; Starovasnik-Žagavec Barbara; Grmek Marko; Slodnjak Ivan; Čuš Anja; Vodušek David B; Pirtošek Zvezdan; Trošt Maja
    Brain perfusion changes in Parkinson's disease: the effect of dopaminergic treatment
    2011
  76. Pirtošek Zvezdan
    Myths and realities of continuous dopaminergic stimulation
    2011
  77. Kapoon R; Pirtošek Z; Frankel JP; Stern GM; Lees AJ; Bottomley JM; Haran NS
    Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468
    1989
  78. Ostrovršnik Jaka; Cvirn Anina; Peterlin-Mašič Lucija
    Amfetamin in metamfetamin: mehanizem delovanja, učinki, zastrupitev in diagnostika
    [Amphetamine and methamphetamine: mechanism of action, effects, poisoning and diagnostics]
    2011
  79. Zaletel Marjan
    Zdravljenje fibromialgije
    [Treatment of fibromyalgia]
    2010
  80. Živin Marko
    Potential applications of dopamine D1 agonist and D2 antagonist LEK-8829
    2010
  81. Gregorič Kramberger Ljudmila; Štukovnik Vita; Čuš Anja; Repovš Grega; Tomše Petra; Pečarič-Meglič Nuška; Garaševič Zdenko; Jensterle Jože; Pirtošek Zvezdan
    Parkinson's disease dementia: clinical correlates of brain SPECT perfusion and treatment
    2010
  82. Kobal J; Švigelj V; Mesec A; Pogačnik T
    Unilateral spatial neglect after dopaminergic agonist treatment of patients with right hemisphere infarction
    1996
  83. Kobal Jan
    Early dopaminergic stimulation after an acute cerebral infarction
    1990
  84. Križaj David
    Mesopic state: cellular mechanisms involved in pre- and post-synaptic mixing of rod and cone signals
    2000
  85. Križaj David; Akopian Abram; Witkovsky Paul
    The effects of L-glutamate, AMPA, quisqualate, and kainate on retinal horizontal cells depend on adaptational state: implications for rod-cone interactions
    1994
  86. Križaj David; Gabriel Robert; Owen Geoffrey W; Witkovsky Paul
    Dopamine D2 receptor-mediated modulation of rod-cone coupling in the Xenopus retina
    1998
  87. Križaj David; Copenhagen David R
    Calcium regulation in photoreceptors
    2002
  88. Witkovsky Paul; Gabriel Robert; Križaj David
    Anatomical and neurochemical characterization of dopaminergic interplexiform processes in mouse and rat retinas
    2008
  89. Trošt M; Šubic A; Steblovnik T; Kirbiš M
    The effect of continuous dopaminergic stimulation with ropinirole on non-motor symptoms, quality of life and autonomic functions in Parkinson's disease patients
    2010
  90. Pal Robert
    Vpliv dopaminergične stimulacije na alternativno izrezovanje pre-mRNA sinaptotagmina 7 pri poskusnih podganah z normalno in s povečano dopaminergično odzivnostjo
    2009
  91. Georgiev Dejan; Danieli Aljoša; Ocepek Lidija; Novak Dominika; Zupančič-Križnar Nina; Trošt Maja; Pirtošek Zvezdan
    Othello syndrome in patients with Parkinson's disease
    2010
  92. Sinkovič Andreja
    Akutno srčno popuščanje pri bolnikih z akutnim srčnim infarktom - diagnoza, prognoza in zdravljenje
    [Acute heart failure in patients with acute myocardial infarction - diagnosis, prognosis and treatment]
    2009
  93. Mele Tina; Čarman-Kržan Marija; Jurič Damijana Mojca
    Regulatory role of monoamine neurotransmitters in astrocytic NT-3 synthesis
    2009
  94. Lainščak Mitja; Coletta Alison P; Sherwi Nasser; Cleland John G
    Clinical trials update from the Heart failure society of America meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1
    2009
  95. Pirtošek Z; Flisar D
    Neuroprotection and dopamine agonists
    2004
  96. Pirtošek Zvezdan
    'Bad guys' among the antiparkinsonian drugs
    2009
  97. Trošt Maja; Dhawan Vijay; Feigin Andrew; Eidelberg David
    PET/SPECT
    2005
  98. Starovasnik Barbara; Repovš Grega; Čuš Anja; Foster Erin; Vodušek David B
    Prospective memory and dopaminergic therapy in early stage Parkinson's disease - a pilot study
    2009
  99. Steblovnik Tjaša; Šubic Ana; Ručna Veronika; Kirbiš Mojca; Trošt Maja
    The effect of continuous dopaminergic stimulation with ropinirole on non-motor symptoms and quality of life in patients with Parkinson's disease
    2009
  100. Kores-Plesničar Blanka; Dolžan Vita; Serretti Alessandro; Mandelli Laura; Zalar Bojan
    Polymorphisms in dopamine receptors genes and symptomatology in patients on maintenance antipsychotic therapy
    2009

1 101 201 301  


Nova poizvedba      Pripombe      Na vrh strani                        Inštitut za biostatistiko in medicinsko informatiko